0A6I Stock Overview A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Soligenix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Soligenix Historical stock prices Current Share Price US$3.09 52 Week High US$18.70 52 Week Low US$1.92 Beta 1.75 1 Month Change -9.42% 3 Month Change -21.19% 1 Year Change -70.30% 3 Year Change -98.39% 5 Year Change n/a Change since IPO -99.18%
Recent News & Updates
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023) Aug 10 See more updates
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Dec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Nov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease Nov 14
Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference Oct 07
Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023) Aug 10
Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™ Aug 02
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma Jul 10
Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma Jun 25
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma May 18
First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023) May 12
Soligenix, Inc., Annual General Meeting, May 23, 2024 May 01
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa Apr 27
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency Apr 04
Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022) Mar 16
No longer forecast to breakeven Mar 16
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board Feb 08
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease Jan 09
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis Jan 05
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses Jan 02
Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period Dec 24
Insufficient new directors Nov 30
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease Nov 30
Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022) Nov 16
Insufficient new directors Nov 16
Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment Aug 11
Insufficient new directors Aug 08
Soligenix, Inc., Annual General Meeting, Sep 21, 2023 Aug 08
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis Jul 12
Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc Jul 10
Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq May 29
First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022) May 18
Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma May 12 Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma May 05
Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors May 04
Insufficient new directors May 04
No longer forecast to breakeven Apr 08
No longer forecast to breakeven Apr 04
Insufficient new directors Feb 27
Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma Feb 15 Shareholder Returns 0A6I GB Biotechs GB Market 7D 0% -5.0% -1.9% 1Y -70.3% -24.4% 2.6%
See full shareholder returns
Return vs Industry: 0A6I underperformed the UK Biotechs industry which returned -24.4% over the past year.
Return vs Market: 0A6I underperformed the UK Market which returned 2.6% over the past year.
Price Volatility Is 0A6I's price volatile compared to industry and market? 0A6I volatility 0A6I Average Weekly Movement 9.6% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A6I's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A6I's weekly volatility has decreased from 55% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
Show more Soligenix, Inc. Fundamentals Summary How do Soligenix's earnings and revenue compare to its market cap? 0A6I fundamental statistics Market cap US$7.13m Earnings (TTM ) -US$7.10m Revenue (TTM ) US$364.18k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A6I income statement (TTM ) Revenue US$364.18k Cost of Revenue US$340.92k Gross Profit US$23.27k Other Expenses US$7.12m Earnings -US$7.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.83 Gross Margin 6.39% Net Profit Margin -1,949.32% Debt/Equity Ratio 34.7%
How did 0A6I perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 16:05 End of Day Share Price 2024/12/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Soligenix, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert LeBoyer Aegis Capital Corporation James Molloy Alliance Global Partners Jonathan Aschoff Brean Capital
Show 4 more analysts 